Literature DB >> 21686634

Diagnostic value of anti-GQ1b antibodies in a patient with relapsing dysarthria and ataxia.

Mark Kuijf1, Liselotte Ruts, Pieter A van Doorn, Peter J Koudstaal, Bart C Jacobs.   

Abstract

Serum antibodies to the ganglioside GQ1b are associated with immune-mediated ophthalmoplegia and ataxia in patients with Miller-Fisher syndrome (MFS) and Guillain-Barré syndrome. A patient with two clinically similar episodes of progressive bulbar signs, ophthalmoplegia and ataxia is reported here. During both episodes the patient required artificial ventilation. Serum anti-GQ1b antibodies were detected during the first episode compatible with MFS, but were absent during the second. Neuroradiological investigations during the second episode showed brain stem ischaemia and obstruction of the left posterior inferior cerebral artery. These findings illustrate that anti-GQ1b serology is a reliable and robust method that helped to distinguish between different causes of relapsing dysarthria and ataxia.

Entities:  

Year:  2009        PMID: 21686634      PMCID: PMC3027713          DOI: 10.1136/bcr.08.2008.0783

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Recurrent Miller Fisher syndrome: clinical and laboratory features and HLA antigens.

Authors:  K Chida; H Nomura; H Konno; S Takase; Y Itoyama
Journal:  J Neurol Sci       Date:  1999-06-01       Impact factor: 3.181

2.  Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies.

Authors:  H J Willison; J Veitch; A V Swan; N Baumann; G Comi; N A Gregson; I Illa; J Zielasek; R A Hughes
Journal:  Eur J Neurol       Date:  1999-01       Impact factor: 6.089

3.  Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA.

Authors:  Mark L Kuijf; Pieter A van Doorn; Anne P Tio-Gillen; Karin Geleijns; C Wim Ang; Herbert Hooijkaas; Wim C J Hop; Bart C Jacobs
Journal:  J Neurol Sci       Date:  2005-09-08       Impact factor: 3.181

4.  Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations.

Authors:  Liselotte Ruts; Rinske van Koningsveld; Pieter A van Doorn
Journal:  Neurology       Date:  2005-07-12       Impact factor: 9.910

Review 5.  Peripheral neuropathies and anti-glycolipid antibodies.

Authors:  Hugh J Willison; Nobuhiro Yuki
Journal:  Brain       Date:  2002-12       Impact factor: 13.501

6.  Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia.

Authors:  S Kusunoki; A Chiba; I Kanazawa
Journal:  Muscle Nerve       Date:  1999-08       Impact factor: 3.217

Review 7.  Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome.

Authors:  Masaaki Odaka; Nobuhiro Yuki; Mitsunori Yamada; Michiaki Koga; Toshihiko Takemi; Koichi Hirata; Satoshi Kuwabara
Journal:  Brain       Date:  2003-07-07       Impact factor: 13.501

8.  Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome.

Authors:  Takahide Nagashima; Michiaki Koga; Masaaki Odaka; Koichi Hirata; Nobuhiro Yuki
Journal:  Arch Neurol       Date:  2007-10

9.  A Haemophilus influenzae strain associated with Fisher syndrome expresses a novel disialylated ganglioside mimic.

Authors:  R Scott Houliston; Michiaki Koga; Jianjun Li; Harold C Jarrell; James C Richards; Varvara Vitiazeva; Elke K H Schweda; Nobuhiro Yuki; Michel Gilbert
Journal:  Biochemistry       Date:  2007-06-13       Impact factor: 3.162

10.  Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.

Authors:  Susan K Halstead; Femke M P Zitman; Peter D Humphreys; Kay Greenshields; Jan J Verschuuren; Bart C Jacobs; Russell P Rother; Jaap J Plomp; Hugh J Willison
Journal:  Brain       Date:  2008-01-08       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.